RxDoctor Payments Data

Anisaa Widyawati Romano Perry, DO

Family Medicine · Andrews, NCNPI 1285073536

Payments from drug & device makers

$1,672in general payments, 2019–2025

Across 41 payments — averaging $40.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$512
  • Amgen$384
  • AbbVie$373
  • Lilly USA, LLC$141
  • Novo Nordisk$62
  • Baxter Healthcare$46
  • plus $154 from 8 others

What the payments were for

  • Food & beverage$1,62697%
  • Other$463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,672 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,657
Medicare patients
69
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$217,476
JardianceEmpagliflozin231$201,355
FarxigaDapagliflozin Propanediol130$109,584
EliquisApixaban116$109,251
LinzessLinaclotide123$96,543
XareltoRivaroxaban124$95,267
HumiraAdalimumab12$81,931
EnbrelEtanercept11$76,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$73,583
Xtampza ErOxycodone Myristate74$62,018
JanuviaSitagliptin Phosphate93$61,943
OtezlaApremilast11$58,458
Tresiba Flextouch U-200Insulin Degludec46$50,975
TezspireTezepelumab-Ekko11$50,122
AptiomEslicarbazepine Acetate25$44,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$62$233,236201 claims
AbbVieLinzess, Humira, Ubrelvy$373$195,210146 claims
AstraZenecaFarxiga, Tezspire, Symbicort$512$176,962211 claims
AmgenEnbrel, Otezla$384$134,79022 claims
Johnson & JohnsonXarelto$15$95,267124 claims
Lilly USA, LLCMounjaro, Trulicity$141$50,60347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Andrews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →